{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:33:04Z","timestamp":1775122384055,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CannaMD"},{"name":"MoreBetter"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Previous research has shown medical cannabis (MC) to help reduce anxiety for some individuals, although most studies show trends using cross-sectional designs or conduct secondary analyses of preexisting data. The present study systematically tracked 416 registered MC patients in Florida across 45 days to assess daily shifts in anxiety levels. Using daily recording software, collected data included the frequency of MC use, other substances (e.g., alcohol, anxiolytic medication), other activities (e.g., exercise, meditation), length of previous MC use, and history of anxiety, among other demographic variables. Using linear mixed-effects modeling, results showed that MC use led to the largest anxiety relief across the 45-day period. When participants only used other substances or engaged in activities on certain days, they also saw anxiety reductions, but the major factor in any measurable change in anxiety when comparing different groups to one another was MC use. Age, sex, history of MC use, length of anxiety, and route of MC administration did not significantly contribute to the findings. Sensitivity analyses revealed that novice and experienced MC patients had similar anxiety reductions, although novice patients had slightly better relief outcomes than experienced patients across the 45 days. The anxiolytic effects of MC documented in this study comport with other published work conducting secondary analyses of preexisting data. Although MC can have anxiogenic effects in some individuals, others find it to be an effective way to reduce daily anxiety.<\/jats:p>","DOI":"10.1038\/s41598-026-39086-2","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:36:24Z","timestamp":1772102184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days"],"prefix":"10.1038","volume":"16","author":[{"given":"R. Nathan","family":"Pipitone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Banai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Walters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Dautrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Schuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Provost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branden","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keenan","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"39086_CR1","unstructured":"American Psychiatric Association. American Adults Express Increasing Anxiousness in Annual Poll; Stress and Sleep are Key Factors Impacting Mental Health. (2024). https:\/\/www.psychiatry.org\/news-room\/news-releases\/annual-poll-adults-express-increasing-anxiousness"},{"issue":"3","key":"39086_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","volume":"21","author":"RC Kessler","year":"2012","unstructured":"Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M. & Wittchen, H. U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the united States. Int. J. Methods Psychiatr Res. 21 (3), 169\u2013184. https:\/\/doi.org\/10.1002\/mpr.1359 (2012).","journal-title":"Int. J. Methods Psychiatr Res."},{"key":"39086_CR3","doi-asserted-by":"publisher","first-page":"e067606","DOI":"10.1136\/bmj-2021-067606","volume":"378","author":"MB Stone","year":"2022","unstructured":"Stone, M. B. et al. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US food and drug administration: individual participant data analysis. BMJ (Clinical Res. ed.). 378, e067606. https:\/\/doi.org\/10.1136\/bmj-2021-067606 (2022).","journal-title":"BMJ (Clinical Res. ed.)"},{"key":"39086_CR4","doi-asserted-by":"publisher","unstructured":"Kirsch, I., Moore, T. J., Scoboria, A. & Nicholls, S. S. The emperor\u2019s new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev. Treat. 5 (1). https:\/\/doi.org\/10.1037\/1522-3736.5.1.523a (2002).","DOI":"10.1037\/1522-3736.5.1.523a"},{"issue":"2","key":"39086_CR5","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","volume":"5","author":"I Kirsch","year":"2008","unstructured":"Kirsch, I. et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med. 5 (2), e45. https:\/\/doi.org\/10.1371\/journal.pmed.0050045 (2008).","journal-title":"PLoS Med."},{"issue":"4","key":"39086_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/neurolint13040059","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff, A. N. et al. Benzodiazepines: Uses, Dangers, and clinical considerations. Neurol. Int. 13 (4), 594\u2013607. https:\/\/doi.org\/10.3390\/neurolint13040059 (2021).","journal-title":"Neurol. Int."},{"issue":"2","key":"39086_CR7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s12035-018-1143-4","volume":"56","author":"AJ Sales","year":"2019","unstructured":"Sales, A. J. et al. Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. Mol. Neurobiol. 56 (2), 1070\u20131081. https:\/\/doi.org\/10.1007\/s12035-018-1143-4 (2019).","journal-title":"Mol. Neurobiol."},{"key":"39086_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2147\/JPR.S134330","volume":"10","author":"JM Corroon Jr","year":"2017","unstructured":"Corroon, J. M. Jr, Mischley, L. K. & Sexton, M. Cannabis as a substitute for prescription drugs - a cross-sectional study. J. Pain Res. 10, 989\u2013998. https:\/\/doi.org\/10.2147\/JPR.S134330 (2017).","journal-title":"J. Pain Res."},{"key":"39086_CR9","doi-asserted-by":"publisher","first-page":"116049","DOI":"10.1016\/j.psychres.2024.116049","volume":"339","author":"K Han","year":"2024","unstructured":"Han, K., Wang, J. Y., Wang, P. Y. & Peng, Y. C. Therapeutic potential of Cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 339, 116049. https:\/\/doi.org\/10.1016\/j.psychres.2024.116049 (2024).","journal-title":"Psychiatry Res."},{"issue":"1","key":"39086_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12967-020-02518-2","volume":"18","author":"L Sharpe","year":"2020","unstructured":"Sharpe, L., Sinclair, J., Kramer, A., de Manincor, M. & Sarris, J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J. Transl Med. 18 (1), 374. https:\/\/doi.org\/10.1186\/s12967-020-02518-2 (2020).","journal-title":"J. Transl Med."},{"issue":"4","key":"39086_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40429-022-00450-7","volume":"9","author":"SD Lichenstein","year":"2022","unstructured":"Lichenstein, S. D. & THC CBD, and anxiety: A review of recent findings on the anxiolytic and anxiogenic effects of cannabis\u2019 primary cannabinoids. Curr. Addict. Rep. 9 (4), 473\u2013485. https:\/\/doi.org\/10.1007\/s40429-022-00450-7 (2022).","journal-title":"Curr. Addict. Rep."},{"key":"39086_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1471-244X-14-136","volume":"14","author":"KK Kedzior","year":"2014","unstructured":"Kedzior, K. K. & Laeber, L. T. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population\u2013a meta-analysis of 31 studies. BMC Psychiatry. 14, 136. https:\/\/doi.org\/10.1186\/1471-244X-14-136 (2014).","journal-title":"BMC Psychiatry"},{"issue":"1","key":"39086_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12888-019-2409-8","volume":"20","author":"J Sarris","year":"2020","unstructured":"Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M. & Firth, J. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 20 (1), 24. https:\/\/doi.org\/10.1186\/s12888-019-2409-8 (2020).","journal-title":"BMC Psychiatry"},{"key":"39086_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2015.12.045","volume":"193","author":"AK Danielsson","year":"2016","unstructured":"Danielsson, A. K., Lundin, A., Agardh, E., Allebeck, P. & Forsell, Y. Cannabis use, depression and anxiety: A 3-year prospective population-based study. J. Affect. Disord. 193, 103\u2013108. https:\/\/doi.org\/10.1016\/j.jad.2015.12.045 (2016).","journal-title":"J. Affect. Disord"},{"key":"39086_CR15","doi-asserted-by":"publisher","unstructured":"Beletsky, A., Liu, C., Lochte, B., Samuel, N. & Grant, I. Cannabis and Anxiety: A Critical Review. Med. Cannabis Cannabinoids. 7(1), 19\u201330 (2016). (2024) https:\/\/doi.org\/10.1159\/000534855Cuttler","DOI":"10.1159\/000534855Cuttler"},{"issue":"3","key":"39086_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/brainsci14030246","volume":"14","author":"S Elsaid","year":"2024","unstructured":"Elsaid, S. et al. Expectancies of the effects of cannabis use in individuals with social anxiety disorder (SAD). Brain Sci. 14 (3), 246. https:\/\/doi.org\/10.3390\/brainsci14030246 (2024).","journal-title":"Brain Sci."},{"issue":"11","key":"39086_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.addbeh.2010.06.017","volume":"35","author":"J Hayaki","year":"2010","unstructured":"Hayaki, J. et al. Expectancies and marijuana use frequency and severity among young females. Addict. Behav. 35 (11), 995\u20131000. https:\/\/doi.org\/10.1016\/j.addbeh.2010.06.017 (2010).","journal-title":"Addict. Behav."},{"key":"39086_CR18","unstructured":"Mueller, J. et al. Effects of cannabis expectancies upon current anxiety and depressive symptoms among women with post-traumatic stress disorder. Cannabis Clinical Outcomes Research Conference: Abstract (2024). Retrieved from: https:\/\/ccorc.mmjoutcomes.org\/2024-abstract-gallery\/effects-of-cannabis-expectancies-upon-current-anxiety-and-depressive-symptoms-among-women-with-post-traumatic-stress-disorder.html"},{"key":"39086_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000512342","volume":"4","author":"MS Rosenthal","year":"2021","unstructured":"Rosenthal, M. S. & Pipitone, R. N. Demographics, perceptions, and use of medical marijuana among patients in Florida. Med. Cannabis Cannabinoids. 4, 13\u201320. https:\/\/doi.org\/10.1159\/000512342 (2021).","journal-title":"Med. Cannabis Cannabinoids"},{"key":"39086_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/21501319221129734","volume":"13","author":"I Kimless","year":"2022","unstructured":"Kimless, I. et al. An observational Cross-Sectional survey exploring the indications for and responses to medical marijuana use in certified patients in Pennsylvania. J. Prim. Care Community Health. 13, 1\u201310. https:\/\/doi.org\/10.1177\/21501319221129734 (2022).","journal-title":"J. Prim. Care Community Health"},{"key":"39086_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2016.0007","volume":"1","author":"M Sexton","year":"2016","unstructured":"Sexton, M., Cuttler, C., Finnell, J. & Mischley, L. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 1, 131\u2013138. https:\/\/doi.org\/10.1089\/can.2016.0007 (2016).","journal-title":"Cannabis Cannabinoid Res."},{"issue":"4","key":"39086_CR22","first-page":"109","volume":"73","author":"CW Webb","year":"2014","unstructured":"Webb, C. W. & Webb, S. M. Therapeutic benefits of cannabis: a patient survey. Hawai\u2019i J. Med. Public. Health. 73 (4), 109\u2013111 (2014).","journal-title":"Hawai\u2019i J. Med. Public. Health"},{"key":"39086_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jsat.2008.08.005","volume":"36","author":"SM Hyman","year":"2009","unstructured":"Hyman, S. M. & Sinha, R. Stress-related factors in cannabis use and misuse: implications for prevention and treatment. J. Subst. Abuse Treat. 36, 400\u2013413. https:\/\/doi.org\/10.1016\/j.jsat.2008.08.005 (2009).","journal-title":"J. Subst. Abuse Treat."},{"key":"39086_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/002204268601600103","volume":"16","author":"LD Johnston","year":"1986","unstructured":"Johnston, L. D. & O\u2019Malley, P. M. Why do the nations\u2019 students use drugs and alcohol? Self-reported reasons from nine National surveys. J. Drug Issues. 16, 29\u201366. https:\/\/doi.org\/10.1177\/002204268601600103 (1986).","journal-title":"J. Drug Issues"},{"key":"39086_CR25","doi-asserted-by":"publisher","first-page":"729800","DOI":"10.3389\/fpsyt.2021.729800","volume":"12","author":"EL Martin","year":"2021","unstructured":"Martin, E. L. et al. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front. Psychiatry. 12, 729800. https:\/\/doi.org\/10.3389\/fpsyt.2021.729800 (2021).","journal-title":"Front. Psychiatry"},{"issue":"8","key":"39086_CR26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.31128\/AJGP-04-21-5936","volume":"51","author":"M Berger","year":"2022","unstructured":"Berger, M., Amminger, G. P. & McGregor, I. S. Medicinal cannabis for the treatment of anxiety disorders. Aust J. Gen. Pract. 51 (8), 586\u2013592. https:\/\/doi.org\/10.31128\/AJGP-04-21-5936 (2022).","journal-title":"Aust J. Gen. Pract."},{"key":"39086_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1136\/bjsports-2022-106195","volume":"57","author":"B Singh","year":"2023","unstructured":"Singh, B. et al. Effectiveness of physical activity interventions for improving depression, anxiety, and distress: an overview of systematic reviews. Br. J. Sports Med. 57, 1203\u20131209. https:\/\/doi.org\/10.1136\/bjsports-2022-106195 (2023).","journal-title":"Br. J. Sports Med."},{"issue":"1","key":"39086_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamapsychiatry.2022.3679","volume":"80","author":"EA Hoge","year":"2023","unstructured":"Hoge, E. A., Bui, E. & Mete, M. Mindfulness-based stress reduction vs Escitalopram for the treatment of adults with anxiety. JAMA Psychiatry. 80 (1), 13\u201321. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.3679 (2023).","journal-title":"JAMA Psychiatry"},{"key":"39086_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jad.2018.04.054","volume":"235","author":"C Cuttler","year":"2018","unstructured":"Cuttler, C., Spradlin, A. & McLaughlin, R. J. A naturalistic examination of the perceived effects of cannabis on negative affect. J. Affect. Disord. 235, 198\u2013205. https:\/\/doi.org\/10.1016\/j.jad.2018.04.054 (2018).","journal-title":"J. Affect. Disord"},{"issue":"2","key":"39086_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.26828\/cannabis\/2024\/000223","volume":"7","author":"RN Pipitone","year":"2024","unstructured":"Pipitone, R. N. et al. Using smartphone technology to track real-time changes in anxiety\/depression symptomatology among Florida cannabis users. Cannabis 7 (2), 123\u2013134. https:\/\/doi.org\/10.26828\/cannabis\/2024\/000223 (2024).","journal-title":"Cannabis"},{"key":"39086_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3389\/fphar.2018.00916","volume":"9","author":"SS Stith","year":"2018","unstructured":"Stith, S. S., Vigil, J. M., Brockelman, F., Keeling, K. & Hall, B. Patient-reported symptom relief following medical cannabis consumption. Front. Pharmacol. 9, 916. https:\/\/doi.org\/10.3389\/fphar.2018.00916 (2018).","journal-title":"Front. Pharmacol."},{"key":"39086_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/can.2016.0010","volume":"1","author":"C Cuttler","year":"2016","unstructured":"Cuttler, C., Mischley, L. & Sexton, M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannabinoid Res. 1, 166\u2013175. https:\/\/doi.org\/10.1089\/can.2016.0010 (2016).","journal-title":"Cannabis Cannabinoid Res."},{"issue":"1","key":"39086_CR33","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1038\/s41598-019-39462-1","volume":"9","author":"SS Stith","year":"2019","unstructured":"Stith, S. S., Vigil, J. M., Brockelman, F., Keeling, K. & Hall, B. The association between cannabis product characteristics and symptom relief. Sci. Rep. 9 (1), 2712. https:\/\/doi.org\/10.1038\/s41598-019-39462-1 (2019).","journal-title":"Sci. Rep."},{"key":"39086_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000536591","volume":"7","author":"MD Kelley","year":"2024","unstructured":"Kelley, M. D., Obaid, M., Miller, E. M., Bowie, M. & Hetter, Z. S. Observational analysis of the influence of medical marijuana use on quality of life in patients. Med. Cannabis Cannabinoids. 7, 44\u201355. https:\/\/doi.org\/10.1159\/000536591 (2024).","journal-title":"Med. Cannabis Cannabinoids"},{"key":"39086_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton, M. The assessment of anxiety States by rating. Br. J. Med. Psychol. 32, 50\u201355 (1959).","journal-title":"Br. J. Med. Psychol."},{"issue":"4","key":"39086_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/mpr.323","volume":"19","author":"LS Matza","year":"2010","unstructured":"Matza, L. S., Morlock, R., Sexton, C., Malley, K. & Feltner, D. Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int. J. Methods Psychiatr Res. 19 (4), 223\u2013232. https:\/\/doi.org\/10.1002\/mpr.323 (2010).","journal-title":"Int. J. Methods Psychiatr Res."},{"key":"39086_CR37","unstructured":"The jamovi project. jamovi (Version 2.5) [Computer Software]. (2024). Retrieved from https:\/\/www.jamovi.org"},{"issue":"5","key":"39086_CR38","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1037\/xge0000014","volume":"143","author":"J Westfall","year":"2014","unstructured":"Westfall, J., Kenny, D. A. & Judd, C. M. Statistical power and optimal design in experiments in which samples of participants respond to samples of stimuli. J. Exp. Psychol. Gen. 143 (5), 2020\u20132045. https:\/\/doi.org\/10.1037\/xge0000014 (2014).","journal-title":"J. Exp. Psychol. Gen."},{"issue":"9","key":"39086_CR39","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"R Wayne","year":"2003","unstructured":"Wayne, R. Evaluating medication effects outside of clinical trials: New-User designs. Am. J. Epidemiol. 158 (9), 915\u2013920. https:\/\/doi.org\/10.1093\/aje\/kwg231 (2003).","journal-title":"Am. J. Epidemiol."},{"issue":"12","key":"39086_CR40","doi-asserted-by":"publisher","first-page":"e70048","DOI":"10.1002\/pds.70048","volume":"33","author":"QL Her","year":"2024","unstructured":"Her, Q. L., Rouette, J., Young, J. C., Webster-Clark, M. & Tazare, J. Core concepts in pharmacoepidemiology: New-User designs. Pharmacoepidemiol Drug Saf. 33 (12), e70048. https:\/\/doi.org\/10.1002\/pds.70048 (2024).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"8","key":"39086_CR41","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jpsychires.2011.03.006","volume":"45","author":"CP McLean","year":"2011","unstructured":"McLean, C. P., Asnaani, A., Litz, B. T. & Hofmann, S. G. Gender differences in anxiety disorders: Prevalence, course of illness, comorbidity and burden of illness. J. Psychiatr Res. 45 (8), 1027\u20131035. https:\/\/doi.org\/10.1016\/j.jpsychires.2011.03.006 (2011).","journal-title":"J. Psychiatr Res."},{"key":"39086_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.07.014","volume":"93","author":"M Colizzi","year":"2018","unstructured":"Colizzi, M. & Bhattacharyya, S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci. Biobehav Rev. 93, 1\u201325. https:\/\/doi.org\/10.1016\/j.neubiorev.2018.07.014 (2018).","journal-title":"Neurosci. Biobehav Rev."},{"key":"39086_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.drugpo.2017.11.008","volume":"52","author":"C Russell","year":"2018","unstructured":"Russell, C., Rueda, S., Room, R., Tyndall, M. & Fischer, B. Routes of administration for cannabis use - basic prevalence and related health outcomes: A scoping review and synthesis. Int. J. Drug Policy. 52, 87\u201396. https:\/\/doi.org\/10.1016\/j.drugpo.2017.11.008 (2018).","journal-title":"Int. J. Drug Policy"},{"key":"39086_CR44","doi-asserted-by":"publisher","unstructured":"Kritikos, A. F., Graham, M., Hodgkin, D. & Pacula, R. L. Medical cannabis dosing trajectories of patients: evidence from sales data. Clin. Ther. S0149-2918 https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.004 (2024). (24)00265-0.","DOI":"10.1016\/j.clinthera.2024.09.004"},{"key":"39086_CR45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drugalcdep.2017.03.030","volume":"177","author":"E Childs","year":"2017","unstructured":"Childs, E., Lutz, J. A. & de Wit, H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug Alcohol Depend. 177, 136\u2013144. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.03.030 (2017).","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"39086_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/jgs.16833","volume":"69","author":"KH Yang","year":"2021","unstructured":"Yang, K. H. et al. Cannabis: an emerging treatment for common symptoms in older adults. J. Am. Geriatr. Soc. 69 (1), 91\u201397. https:\/\/doi.org\/10.1111\/jgs.16833 (2021).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"7","key":"39086_CR47","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00213-021-05823-w","volume":"238","author":"TC Spinella","year":"2021","unstructured":"Spinella, T. C., Stewart, S. H., Naugler, J., Yakovenko, I. & Barrett, S. P. Evaluating Cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study. Psychopharmacol 238 (7), 1965\u20131977. https:\/\/doi.org\/10.1007\/s00213-021-05823-w (2021).","journal-title":"Psychopharmacol"},{"key":"39086_CR48","unstructured":"Rosenthal, M. S. Drugs: Mind, Body, and Society (2e)Oxford University Press, (2022)."},{"key":"39086_CR49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1360-0443.2012.04015.x","volume":"108","author":"L Degenhardt","year":"2013","unstructured":"Degenhardt, L. et al. Adolescent cannabis use and mental health. Addict 108, 124\u2013133. https:\/\/doi.org\/10.1111\/j.1360-0443.2012.04015.x (2013).","journal-title":"Addict"},{"issue":"1","key":"39086_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/YCO.0000000000000566","volume":"33","author":"M Van Ameringen","year":"2020","unstructured":"Van Ameringen, M., Zhang, J., Patterson, B. & Turna, J. The role of cannabis in treating anxiety: an update. Curr. Opin. Psychiatry. 33 (1), 1\u20137. https:\/\/doi.org\/10.1097\/YCO.0000000000000566 (2020).","journal-title":"Curr. Opin. Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39086-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:38:22Z","timestamp":1775119102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39086-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39086"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39086-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MoreBetter (www.morebetter.ltd) is a software, data, and research firm that's been running longitudinal studies on the use and efficacy of cannabinoids since 2016. MoreBetter created an app called Releaf App which is a free medical cannabis journaling app. They do not have a clinic or sell cannabis products of any kind. There was no collection of money from participants. The individuals from MoreBetter did not help with any hypotheses, design, analysis, interpretation of results, or decision to submit for publication. They assisted in building the survey according to our interests. They helped with data collection and sent us de-identified data to analyze. All participants were entered into a raffle after the study was completed to receive Amazon gift cards. Participants were told they may receive up to $250 amazon gift card. We sent out a total of $1,000 worth of amazon gift cards. Those were broken down into nine raffle winners. Two received $250, two received $100, two received $75, and three received $50. MoreBetter and CannaMD provided $1,000 participant compensation (split between MoreBetter and CannaMD) and MoreBetter funded: Participant recruitment costs, Software costs (from their own study management software, Penzai), and SMS costs to send the study questions to all participants for 45 days.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11124"}}